神经基因公司
NGNE
23.25
-0.70
-2.92%
神经基因公司
US · NGNE
#3726 按市值排名
23.25
-0.70
-2.92%
实时 - 追踪5344个代码 - 心跳于20秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例下降了24.3个百分点。
机构持股
- 机构持股比例
- 88.91% -24.31pp
- 机构数量
- 143 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund38.77%
Mutual Fund24.64%
VC/PE Fund18.11%
Individual/Insider7.01%
Public Company4.91%
Sovereign Wealth Fund1.84%
Private Company0.44%
Insurance Company0.12%
Other4.09%
主要股东 截至 2026-06-30
Samsara BioCapital LLC
8.58% · 1.72M 股
Casdin Capital, LLC
7.72% · 1.55M 股
Redmile Group, LLC
7.06% · 1.41M 股
RTW Investments, LP
6.81% · 1.36M 股
Rachel McMinn
6.64% · 1.33M 股
EcoR1 Capital, LLC
6.35% · 1.27M 股
BlackRock
5.29% · 1.06M 股
Baker Bros. Advisors LP
4.96% · 991.69K 股
Balyasny Asset Management L.P.
4.09% · 818.71K 股
Trails Edge Capital Partners, LP
3.57% · 714.89K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 37次买入 · 11次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Rachel McMinn | Chief Executive Officer | 6.64% |
| Christine Cvijic | President, CFO & Secretary | 0.19% |
| Cory Freedland | Director | 0.17% |
| Julie Jordan | Chief Medical Officer | 0.01% |
| Robert Baffi | Director | -- |
| Rohan Palekar | Director | -- |
| Sarah Noonberg | Director | -- |
| Samsara Biocapital, L.P. | -- | -- |
| Samsara BioCapital LLC | -- | -- |
| Robert Woods | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-21 | Rachel McMinn | Chief Executive Officer | Derivative Exercise and Retained | +756 | $25.32 |
| 2026-07-06 | Christine Cvijic | President, CFO & Secretary | Automatic Disposition | -4,800 | $36.02–36.13 |
| 2026-07-01 | Christine Cvijic | President, CFO & Secretary | Automatic Disposition | -4,800 | $34.06–35.23 |
| 2026-05-05 | Christine Cvijic | President, CFO & Secretary | Automatic Disposition | -9,600 | $30.07–32.44 |
| 2026-05-04 | Christina Shafer | Chief Commercial Officer | Other Derivative Acquisition | +120,000 | $28.94 |
| 2026-03-25 | Rachel McMinn | Chief Executive Officer | Open Market Disposition | -3,352 | $22.07 |
| 2026-03-25 | Christine Cvijic | President, CFO & Secretary | Open Market Disposition | -2,558 | $21.62 |
| 2026-03-25 | Julie Jordan | Chief Medical Officer | Open Market Disposition | -828 | $21.89 |
| 2026-03-12 | Christine Cvijic | President, CFO & Secretary | Open Market Disposition | -4,045 | $20.42–22.02 |
| 2026-03-12 | Stuart Cobb | Chief Scientific Officer | Automatic Disposition | -6,797 | $20.41–22.08 |
| 2026-02-26 | Christine Cvijic | President, CFO & Secretary | Automatic Disposition | -4,800 | $25.11 |
| 2026-02-19 | Robert Baffi | Director | Other Derivative Acquisition | +12,050 | $17.64 |
| 2026-02-19 | Rohan Palekar | Director | Other Derivative Acquisition | +12,050 | $17.64 |
| 2026-02-19 | Rachel McMinn | Chief Executive Officer | Other Acquisition | +25,900 | -- |
| 2026-02-19 | Rachel McMinn | Chief Executive Officer | Other Derivative Acquisition | +155,100 | $17.64 |
| 2026-02-19 | Sarah Noonberg | Director | Other Derivative Acquisition | +12,050 | $17.64 |
| 2026-02-19 | Christine Cvijic | President, CFO & Secretary | Other Acquisition | +22,000 | -- |
| 2026-02-19 | Christine Cvijic | President, CFO & Secretary | Other Derivative Acquisition | +131,900 | $17.64 |
| 2026-02-19 | Cory Freedland | Director | Other Derivative Acquisition | +12,050 | $17.64 |
| 2026-02-19 | Robert Woods | Independent Director | Other Derivative Acquisition | +12,050 | $17.64 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
神经基因公司 讨论区 0 条评论